BTG3 and inflammatory bowel disease: Previous studies had also shown that the prevalence of ANA positivity among patients with IBD (13.6–53.5%) was higher than that in the global healthy population (Barahona-Garrido et al., 2009; Garcia-Planella et al., 2003; García et al., 2022); however, recent studies indicate that the prevalence of ANA titers of >1:80 is increasing in healthy populations, ranging from 14.01% to 16.1% (Dinse et al., 2022; Li et al., 2019).